BIO.B — Bio Rad Laboratories Income Statement
0.000.00%
Last trade - 00:00- $6.80bn
- $6.33bn
- $2.57bn
- 91
- 61
- 14
- 55
Annual income statement for Bio Rad Laboratories, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2,546 | 2,923 | 2,802 | 2,671 | 2,567 |
| Cost of Revenue | |||||
| Gross Profit | 1,438 | 1,663 | 1,568 | 1,431 | 1,379 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 2,117 | 2,423 | 2,330 | 2,333 | 2,298 |
| Operating Profit | 428 | 500 | 472 | 338 | 269 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 4,918 | 5,449 | -4,704 | -850 | -2,343 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3,814 | 4,254 | -3,628 | -637 | -1,844 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 3,814 | 4,254 | -3,628 | -637 | -1,844 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3,814 | 4,254 | -3,628 | -637 | -1,844 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 126 | 143 | -121 | -21.2 | -64.3 |